<div id="readability-page-1"><div><p>GSK PLC - London-based pharmaceuticals firm - Announces agreement with the US government to lower the cost of prescription medicines for American patients, including GSK's portfolio for respiratory conditions such as asthma and COPD. Says it will lower the price of certain medicines in Medicaid and &#34;launch new products with a more balanced pricing approach&#34;, and will make most of its inhaled respiratory portfolio and other products available to patients on a direct purchasing platform with savings of up to 66%. Furthermore, it intends to further support the US supply chain for critical medicines by securing a reserve of albuterol, the active ingredient used in many inhalers to relieve the symptoms of asthma and COPD, for the US.</p><p>Chief Executive Officer Emma Walmsley says: &#34;Today's announcement builds on GSK's strong track record of increasing access and improving the affordability of its medicines worldwide, including an ongoing commitment to responsible pricing. GSK has been at the forefront of respiratory innovation for decades – helping millions of Americans prevent and treat chronic respiratory diseases such as asthma and COPD. Through this agreement, GSK will ensure patients have access to the current portfolio of respiratory medicines while bringing the next wave of innovation to American patients.&#34;</p><p>Current stock price: 1,822.00 pence, up 0.5% on Friday in London</p><p> 12-month change: up 38%</p><p>By Emma Curzon, Alliance News reporter</p><p>Comments and questions to newsroom@alliancenews.com</p><p>Copyright 2025 Alliance News Ltd. All Rights Reserved.</p></div></div>

葛蘭素史克

<p>葛蘭素史克（GSK PLC）是一家總部位於倫敦的製藥公司，已與美國政府達成協議，以降低美國患者的處方藥費用，重點關注哮喘和慢性阻塞性肺病等呼吸系統疾病。該協議包括降低醫療補助計劃中的藥品價格，並推出具有平衡定價的新產品。GSK 將為其吸入型呼吸藥物組合提供高達 66% 的折扣，併為美國確保一批沙丁胺醇。首席執行官艾瑪·沃姆斯利（Emma Walmsley）強調了 GSK 對可負擔藥物獲取和呼吸系統創新的承諾</p>

葛蘭素史克宣佈與美國政府達成藥品價格協議